Logo image of LUCD

LUCID DIAGNOSTICS INC (LUCD) Stock Fundamental Analysis

NASDAQ:LUCD - Nasdaq - US54948X1090 - Common Stock - Currency: USD

1.31  -0.02 (-1.5%)

Fundamental Rating

2

Taking everything into account, LUCD scores 2 out of 10 in our fundamental rating. LUCD was compared to 189 industry peers in the Health Care Equipment & Supplies industry. LUCD may be in some trouble as it scores bad on both profitability and health. LUCD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LUCD had negative earnings in the past year.
In the past year LUCD has reported a negative cash flow from operations.
LUCD had negative earnings in each of the past 5 years.
In the past 5 years LUCD always reported negative operating cash flow.
LUCD Yearly Net Income VS EBIT VS OCF VS FCFLUCD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

LUCD's Return On Assets of -172.64% is on the low side compared to the rest of the industry. LUCD is outperformed by 91.53% of its industry peers.
LUCD has a worse Return On Equity (-983.58%) than 87.83% of its industry peers.
Industry RankSector Rank
ROA -172.64%
ROE -983.58%
ROIC N/A
ROA(3y)-179.51%
ROA(5y)-192.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LUCD Yearly ROA, ROE, ROICLUCD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LUCD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LUCD Yearly Profit, Operating, Gross MarginsLUCD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K

More info and screens

1

2. Health

2.1 Basic Checks

LUCD does not have a ROIC to compare to the WACC, probably because it is not profitable.
LUCD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LUCD has been increased compared to 5 years ago.
The debt/assets ratio for LUCD has been reduced compared to a year ago.
LUCD Yearly Shares OutstandingLUCD Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
LUCD Yearly Total Debt VS Total AssetsLUCD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -10.71, we must say that LUCD is in the distress zone and has some risk of bankruptcy.
LUCD has a Altman-Z score of -10.71. This is in the lower half of the industry: LUCD underperforms 79.37% of its industry peers.
A Debt/Equity ratio of 3.45 is on the high side and indicates that LUCD has dependencies on debt financing.
The Debt to Equity ratio of LUCD (3.45) is worse than 87.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.45
Debt/FCF N/A
Altman-Z -10.71
ROIC/WACCN/A
WACC8.45%
LUCD Yearly LT Debt VS Equity VS FCFLUCD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.07 indicates that LUCD should not have too much problems paying its short term obligations.
LUCD has a Current ratio of 1.07. This is amonst the worse of the industry: LUCD underperforms 87.83% of its industry peers.
LUCD has a Quick Ratio of 1.05. This is a normal value and indicates that LUCD is financially healthy and should not expect problems in meeting its short term obligations.
LUCD has a Quick ratio of 1.05. This is in the lower half of the industry: LUCD underperforms 74.60% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 1.05
LUCD Yearly Current Assets VS Current LiabilitesLUCD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

LUCD shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.28%.
LUCD shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.00%.
Measured over the past years, LUCD shows a very strong growth in Revenue. The Revenue has been growing by 105.61% on average per year.
EPS 1Y (TTM)3.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
Revenue 1Y (TTM)79%
Revenue growth 3Y105.61%
Revenue growth 5YN/A
Sales Q2Q%-17.28%

3.2 Future

LUCD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.33% yearly.
The Revenue is expected to grow by 84.68% on average over the next years. This is a very strong growth
EPS Next Y42.61%
EPS Next 2Y30.68%
EPS Next 3Y23.2%
EPS Next 5Y12.33%
Revenue Next Year85.33%
Revenue Next 2Y138.92%
Revenue Next 3Y110.39%
Revenue Next 5Y84.68%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
LUCD Yearly Revenue VS EstimatesLUCD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
LUCD Yearly EPS VS EstimatesLUCD Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LUCD. In the last year negative earnings were reported.
Also next year LUCD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUCD Price Earnings VS Forward Price EarningsLUCD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUCD Per share dataLUCD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as LUCD's earnings are expected to grow with 23.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.68%
EPS Next 3Y23.2%

More info and screens

0

5. Dividend

5.1 Amount

LUCD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUCID DIAGNOSTICS INC

NASDAQ:LUCD (5/22/2025, 9:54:35 AM)

1.31

-0.02 (-1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners5.47%
Inst Owner Change183.35%
Ins Owners8.08%
Ins Owner Change5.09%
Market Cap137.98M
Analysts83.33
Price Target3.83 (192.37%)
Short Float %1.98%
Short Ratio1.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.14%
Min EPS beat(2)-11.41%
Max EPS beat(2)7.12%
EPS beat(4)1
Avg EPS beat(4)-13.28%
Min EPS beat(4)-46.33%
Max EPS beat(4)7.12%
EPS beat(8)3
Avg EPS beat(8)-6.65%
EPS beat(12)5
Avg EPS beat(12)-2.03%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.37%
Min Revenue beat(2)-17.51%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-11.22%
Min Revenue beat(4)-21.98%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-2.9%
Revenue beat(12)2
Avg Revenue beat(12)-26.88%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.27%
PT rev (3m)-6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.61%
EPS NY rev (1m)-4.36%
EPS NY rev (3m)10.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-21.1%
Revenue NY rev (1m)-10.52%
Revenue NY rev (3m)-22.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.75
P/FCF N/A
P/OCF N/A
P/B 25.59
P/tB 29.64
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.04
BVpS0.05
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -172.64%
ROE -983.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.51%
ROA(5y)-192.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 3.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.36%
Cap/Sales 14.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 1.05
Altman-Z -10.71
F-Score6
WACC8.45%
ROIC/WACCN/A
Cap/Depr(3y)37.04%
Cap/Depr(5y)N/A
Cap/Sales(3y)87.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
EPS Next Y42.61%
EPS Next 2Y30.68%
EPS Next 3Y23.2%
EPS Next 5Y12.33%
Revenue 1Y (TTM)79%
Revenue growth 3Y105.61%
Revenue growth 5YN/A
Sales Q2Q%-17.28%
Revenue Next Year85.33%
Revenue Next 2Y138.92%
Revenue Next 3Y110.39%
Revenue Next 5Y84.68%
EBIT growth 1Y4.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.73%
EBIT Next 3Y5.62%
EBIT Next 5Y8.76%
FCF growth 1Y-35.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.5%
OCF growth 3YN/A
OCF growth 5YN/A